TY - JOUR
T1 - Lack of association between acyclovir use and survival in patients with advanced human immunodeficiency virus disease treated with zidovudine
AU - Gallant, Joel E.
AU - Moore, Richard D.
AU - Keruly, Jeanne
AU - Richman, Douglas D.
AU - Richman, Richard E.
AU - Chaisson, Richard E.
N1 - Funding Information:
John Bartlett, Sharon McAvinue, Johns Hopkins University School of Medicine, Baltimore; Yvonne Bryson and Helene Cohen, UCLA School of Medicine, Los Angeles; Margaret Fischl and Terry Bolin, University of Miami, FL; Harold Kessler and Yvonne Burrough, Rush Presbyterian-St. Luke's Medical Center, Chicago; Donna Mildvan and Alice Fox, Beth Israel Medical Center, New York; Douglas Richman and Ben Freeman, University of California, San Diego; Gary Simon and Kathy Ward Grabowy, George Washington University Medical Center, Washington, DC; David Chernoff and Patricia Duff, University of California, San Francisco; Sumner Thompson and Kara Barrett, Emory University, Atlanta; Robert Awe, Ruby Chapman, and Shirley Leonard, Lyndon Baines Johnson General Hospital, Houston; Paul Turner and Marge Hawkins, Kaiser Permanente Medical Group, Los Angeles; Henry Murray and Jill Bowers, Cornell University Medical Center, New York; Clifford Lane, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Hugh Tilson, Elizabeth Andrews, and Lynn Smiley, Burroughs Wellcome Co., Research Triangle Park, NC.
PY - 1995/8
Y1 - 1995/8
N2 - To evaluate the association between acyclovir use and survival in patients with advanced human immunodeficiency virus infection, observational data from 1044 persons with AIDS or AIDS-related complex (ARC) and ≤250 CD4 cells/mm3following initiation of zidovudine were analyzed. Of these patients, 336 (32%) received regular acyclovir (≥6 weeks in 2 months). There were no differences in mortality data between acyclovir users and nonusers overall or when analyzed from 1 year after first use of zidovudine, from time of AIDS in those with ARC at enrollment, from patients with AIDS or < 100 CD4 cells/mm3at enrollment, or from patients taking acyclovir for up to 10 months. Acyclovir use was associated with increased mortality (relative hazard, 1.28; P =.057) independent of herpesvirus infections and of other characteristics associated with mortality. In this study, the use of acyclovir at doses for treatment of herpes simplex virus infection in combination with zidovudine was not associated with prolonged survival.
AB - To evaluate the association between acyclovir use and survival in patients with advanced human immunodeficiency virus infection, observational data from 1044 persons with AIDS or AIDS-related complex (ARC) and ≤250 CD4 cells/mm3following initiation of zidovudine were analyzed. Of these patients, 336 (32%) received regular acyclovir (≥6 weeks in 2 months). There were no differences in mortality data between acyclovir users and nonusers overall or when analyzed from 1 year after first use of zidovudine, from time of AIDS in those with ARC at enrollment, from patients with AIDS or < 100 CD4 cells/mm3at enrollment, or from patients taking acyclovir for up to 10 months. Acyclovir use was associated with increased mortality (relative hazard, 1.28; P =.057) independent of herpesvirus infections and of other characteristics associated with mortality. In this study, the use of acyclovir at doses for treatment of herpes simplex virus infection in combination with zidovudine was not associated with prolonged survival.
UR - http://www.scopus.com/inward/record.url?scp=0029125606&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029125606&partnerID=8YFLogxK
U2 - 10.1093/infdis/172.2.346
DO - 10.1093/infdis/172.2.346
M3 - Article
C2 - 7622876
AN - SCOPUS:0029125606
VL - 172
SP - 346
EP - 352
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 2
ER -